Echinacea for Influenza (Flu)
Echinacea is not a proven treatment or preventive for influenza. The few flu-specific human trials are small and industry-funded, so it should never replace vaccination or antiviral drugs.
Why this grade7-layer evidence engine
The grade is Weak (Tier C) because genuine influenza-specific evidence is thin and conflicted. Only two human trials address flu directly: Raus 2015 (PMID 26265958), a 473-patient RCT in which an Echinaforce hot drink was "noninferior" to the antiviral oseltamivir (90.1% vs 84.8% recovery, fewer complications), and a 201-child prevention trial (PMID 33832544) reporting fewer flu detections (3 vs 20). Both were funded by the maker A. Vogel, and the engine flags this industry-funding conflict.
Crucially, the one high-quality source, the 2014 Cochrane review (PMID 24554461), studied the common cold rather than lab-confirmed influenza, finding no significant prevention benefit and only a 10-20% pooled risk reduction. It cannot be read as flu evidence. Noninferiority to oseltamivir is also limited, since that drug has only modest efficacy itself.
Regulators and clinics reinforce caution. The US FDA treats echinacea cold/flu cure claims as "unapproved new drugs"; the UK MHRA registers it only "based on traditional use," and Mayo Clinic says any cold benefit "may be too minor to notice." Cleveland Clinic discourages it, and CDC/IDSA recommend vaccination and antivirals instead. Asteraceae-allergy and autoimmune cautions also apply.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.429
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status